TomoTherapy Incorporated, maker of the Hi·Art® treatment system for advanced radiation therapy, has entered into an agreement to acquire privately held linear accelerator manufacturer Chengdu Twin Peak Accelerator Technology Inc., based in Chengdu, China.

A key component in radiation therapy systems, a linear accelerator (linac) is used to create high-energy x-rays for cancer treatments. It is designed, developed and manufactured by Twin Peak and will be used to supplement TomoTherapy's existing supply source.

Fred Robertson, CEO of TomoTherapy, said that the acquisition of Twin Peak represents a substantial advance in the company's ability to control the quality and features of their products, and is a piece of the longer-term strategy of reducing the cost of the Hi·Art treatment system to improve margins.
About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO.

More Voices